A Phase 1/2 Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa

Trial Profile

A Phase 1/2 Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 May 2017

At a glance

  • Drugs Adipose stem cell therapy Anterogen (Primary)
  • Indications Epidermolysis bullosa
  • Focus Adverse reactions
  • Sponsors Anterogen
  • Most Recent Events

    • 19 May 2017 Results from this trial published in an Abeona therapeutics Media Release.
    • 19 May 2017 According to an Abeona Therapeutics media release, top-line data from this trial will be presented at Society for Investigative Dermatology Conference.
    • 27 Dec 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top